GBA carriers with PD are otherwise clinically similar to idiopathic PD patients, with indistinguishable response to dopaminergic medications, slightly younger age of onset by about 4 years, and higher incidence of cognitive decline [12,13]. This evidence concerns the gene GBA1 and Parkinson disease.